New mRNA shot aims to tame stubborn gout
NCT ID NCT07587684
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This early-stage trial tests a new mRNA medicine called IN026 in 16 adults with refractory gout — gout that doesn't get better with standard treatments. The drug is given as an IV infusion and is designed to lower uric acid levels and shrink uric acid crystals (tophi). The main goal is to check safety, but researchers will also see if it helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IN026 (an mRNA therapy given as an IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-control gout that doesn't respond to standard therapies.
- What could go wrong
- This is a very early, small Phase 1 trial with only 16 participants, so it's mainly checking safety. It may not lower uric acid effectively or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.